药物中磺酸酯类基因毒性杂质测定方法研究进展

介绍磺酸酯类基因毒性杂质的分析方法,包括高效液相色谱法、液相色谱-质谱联用法、气相色谱法和气相色谱-质谱联用法等。高效液相色谱法操作简单,应用广泛,能实现绝大多数化合物的分离、分析;液相色谱-质谱联用法具有灵敏度高、准度高、特异性高等特点;气相色谱应用于易分离气体和易挥发的成分的检测,灵敏度高,专属性强;气相色谱-质谱联用法具有分析速度快、分离效能好、灵敏度高、选择性强的特点。开发通用、简便、灵敏度高的分析检测方法,为更好地监测磺酸酯类基因毒性杂质提供理论参考。     

液相色谱-串联质谱法测定吉非替尼中4种基因毒性杂质

建立了一种同时测定吉非替尼中4种基因毒性杂质3-氯-4-氟苯胺、3,4-二氟苯胺、3-氟-4-氯苯胺和3,4-二氯苯胺的高效液相色谱-串联质谱（HPLC-MS/MS）方法。用Inertsil ODS-3柱（100 mm×3.0 mm,3μm）为色谱柱,以0.1%（体积分数,下同）甲酸水溶液-0.1%甲酸乙腈溶液为流动相,在电喷雾正离子模式下进行测定。该方法在特异性、线性、精密度、准确性、稳定性和耐用性方面得到了验证。4种基因毒性杂质在0.6~96.0μg/L范围内与峰面积呈良好线性关系。检测限和定量限分别为0.2~2.0μg/L和0.6~6.0μg/L。所有杂质的回收率为91.0%~98.5%。检测后,在批号16052301和R16052501-1样品中仅检测到3-氯-4-氟苯胺,但低于杂质限度（6 mg/L）。该方法简便可靠,可用于吉非替尼中4种基因毒性杂质的测定,并为质量控制提供参考。     

药物中元素杂质检测技术研究最新进展

元素杂质的控制一直是药物研发过程中的重要问题,某些元素杂质不仅会对药物的稳定性、保质期产生不利影响,还可能因为潜在的毒性引发药物副作用。欧盟和美国对元素杂质的控制越来越严格,USP<232>、USP<233>、ICH Q3D对元素杂质的分类和控制都提出了新的要求,中国于2017年6月加入ICH后对此项目的检测也应向国际靠拢,因此建立有效的检测方法尤其重要。该文从样品制备、元素杂质的快速筛查方法及仪器分析方法等方面介绍了近年来药物中元素杂质分析的最新进展,以期为药品中的元素杂质分析提供理论支持和技术参考。     

翻译后修饰蛋白质组学分离方法的研究进展

蛋白质翻译后修饰（PTMs）是调节细胞内生理活动的重要途径。该文总结了近年来PTMs蛋白质组学相关的分离方法,包括反相（RP）色谱法、离子交换（IEX）色谱法、亲水相互作用色谱（HILIC）法、多孔石墨化碳（PGC）色谱法、毛细管电泳（CE）法及分子筛色谱（SEC）法等。这些新方法为磷酸化、乙酰化、糖基化等PTM肽段或蛋白质的鉴定提供了更高的分离度和灵敏度。此外,该文也介绍了蛋白质领域其他重要分离方法的研究进展,这些方法可能被进一步应用于PTMs蛋白质组学的研究中。     

乙嘧酚磺酸酯波谱表征研究

利用红外光谱（IR）、核磁共振（NMR）、有机质谱（MS）、紫外光谱（UV）对乙嘧酚磺酸酯进行了波谱表征,对其化学结构中官能团特征红外吸收、核磁共振1H的化学位移、质谱准分子离子、紫外吸收进行解析,并获得了相关波谱图,为乙嘧酚磺酸酯的合成及其产品质量控制提供参考。     

分散液-液微萃取结合HPLC测定富马酸替诺福韦酯中9-丙烯基腺嘌呤

将分散液-液微萃取与HPLC结合,建立了测定富马酸替诺福韦酯中的基因毒性杂质9-丙烯基腺嘌呤的分析方法。同时对影响萃取效率的各项参数如萃取剂的种类及用量、分散剂的种类及用量、溶液体系pH、离子强度及萃取时间等进行了优化。将样品用水溶解,调节溶液至pH 9. 0,NaCl浓度为3 g/L,以300μL正庚醇为萃取剂,萃取时间为3 min,3000 r/min离心3 min,取上层进行液相分析。结果表明,9-丙烯基腺嘌呤在1. 22～366 ng/mL范围内线性关系良好,检测限为0. 41 ng/mL,平均回收率为96. 2%～97. 8%,RSD 1. 0%。方法满足富马酸替诺福韦酯中基因毒性杂质9-丙烯基腺嘌呤的测定要求。     

反相高效液相色谱法同时测定防晒化妆品中的防腐剂和防晒剂

 用反相高效液相色谱法实现了对化妆品中4种防腐剂（对羟基苯甲酸甲酯、对羟基苯甲酸乙酯、对羟基苯甲酸丙酯、对羟基苯甲酸丁酯）和6种防晒剂（2-羟基-4-甲氧基二苯甲酮-5-磺酸、2-羟基-4-甲氧基二苯甲酮、水杨酸苯酯、对甲氧基肉桂酸辛酯、对二甲基氨基苯甲酸辛酯、水杨酸辛酯）的分离测定。各组分回收率（n=6）为87.2%～106.5%;相对标准偏差（n=6）为1.2%～3.3%。     

乙腈-无机盐-水双水相体系萃取-气相色谱法检测鱼肉中拟除虫菊酯

以乙腈-无机盐-水双水相体系,建立了一种环保、高效的用于气相色谱法检测鱼肉样品中拟除虫菊酯的样品前处理方法.实验利用荧光猝灭法与气相色谱法研究了拟除虫菊酯药物在以蛋白质为主要基质的水产品中的存在状态,考察了双水相的形成条件,并探讨了蛋白质对双水相萃取率的影响.结果表明,拟除虫菊酯药物通过疏水作用力与蛋白质牢固结合.以体积分数为80%的乙腈水溶液作为萃取液可以引起水产品中的蛋白质基质缓慢而彻底地变性,从而充分释放与蛋白质结合的药物,实现拟除虫菊酯的均相高效萃取.80%的乙腈水溶液具有较强的化学极性,因而在双水相系统上相中与药物残留共同萃入的脂溶性杂质较少,萃取液净化步骤大大简化.在双水相上相中加入无水MgSO4,PSA去除水分与杂质后,直接进样进行气相色谱检测.该方法用于鱼肉样品中六种拟除虫菊酯的萃取检测,回收率为81.1%～96.4%,检出限为8～14ng·mL-1.     

麻黄碱对映异构体的柱前手性衍生化-反相高效液相色谱法拆分

建立了一种用柱前手性衍生化－反相高效液相色谱法分析麻黄碱对映异构体的方法;以（一）－氯化酸薄荷醇酯作为手性衍生化试剂,（－）－麻黄碱与（＋）－麻黄碱衍生化后生成－对非对映异构体,选用Hypersil C18柱,以乙腈-水－乙酸－三乙胺（体积比29：20：0．2：0．01）为流动相,在254nm下检测,色谱经分经电喷雾离子阱多级质谱分析验证;非对称异构体色谱峰的保留时间分别为17．1min和18．3min,分离度为1．6;该法操作简单、快速、重现性好,可用于药品质量控制和对映体选择性药物动力学研究。     

毛细管色谱法测定苯类产品馏程

彩和毛细管色谱法,以OV101石英毛细管色谱柱为分离柱,用氢火焰离子化检测器（FID）和面积归一法计算出各影响苯类产品馏程的杂质百分含量,通过建立馏程与杂质百分含量关系式,建立了用毛细管色谱法测定杂质百分含量代替测定苯类产品馏程的国家标准方法GB／T3146－82（色谱法）中的峰高,方法测得的馏程数据与GB／T3146－82（色谱法）的测定值相一致,且操作简便,分析时间短。     

Identification,control strategies,and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: A comprehensive review

Potential genotoxic impurities in pharmaceuticals at trace levels are of increasing concern to both pharmaceutical industries and regulatory agencies due to their possibility for human carcinogenesis. Molecular functional groups that render starting materials and synthetic intermediates as reactive building blocks for small molecules may also be responsible for their genotoxicity. Determination of these genotoxic impurities at trace levels requires highly sensitive and selective analytical methodologies, which poses tremendous challenges on analytical communities in pharmaceutical research and development. Experimental guidance for the analytical determination of some important classes of genotoxic impurities is still unavailable in the literature. Therefore, the present review explores the structural alerts of commonly encountered potential genotoxic impurities, draft guidance of various regulatory authorities in order to control the level of impurities in drug substances and to assess their toxicity. This review also describes the analytical considerations for the determination of potential genotoxic impurities at trace levels and finally few case studies are also discussed for the determination of some important classes of potential genotoxic impurities. It is the authors’ intention to provide a complete strategy that helps analytical scientists for the analysis of such potential genotoxic impurities in pharmaceuticals.     

Recent advances in analysis of hazardous genotoxic impurities in pharmaceuticals by HPLC,GC, and CE

Nowadays, genotoxic impurities in pharmaceuticals at lower levels are of increasing concerns not only to pharmaceutical industries but also for the regulatory agencies due to their risks for human carcinogenesis and, thus, requiring manufacturers to pay extra attention for their analysis and control. The need to determine these impurities at trace levels, based on the threshold of toxicological and daily dose, taking into consideration the often reactive and labile nature of genotoxic impurities, which poses significant analytical challenges. Therefore, sensitive and sophisticated analytical methodologies are deemed necessary in order to be able to test and control genotoxic impurities in drug substances. This review demonstrates the approaches reported in the literature for the analysis of the hazardous genotoxic impurities and the strategies used to enhance the sensitivity such as using ion spray-mass spectrometry and the separation techniques for the analysis of such impurities.     

Evolution of regulatory aspects of genotoxic impurities in pharmaceuticals: Survival of the fittest

The genotoxic impurities (GIs) are carcinogenic hence its management during synthesis of pharmaceuticals is very important to be detected even in trace level for the safe use of the drugs. The presence of drug substance/drug product DNA-reactive impurities poses a significant problem for drug regulators as well as industry. There are several regulatory guidelines and position papers focused on controlling the amount of impurities within the specified limits. The present compilation gives an account of updated information about GIs and reviews the regulatory aspects for GIs in active pharmaceutical ingredients/drug formulations. A detailed discussion about control strategies in the context of GIs is also described precisely. The analysis of GIs is a challenging and complex aspect of the drug development process. Control and determination of these impurities at ppm or ppb levels are significant challenges for analysts, therefore the approaches for the analysis of GIs have also been discussed.     

Role of in silico genotoxicity tools in the regulatory assessment of pharmaceutical impurities

The toxicological assessment of genotoxic impurities is important in the regulatory framework for pharmaceuticals. In this context, the application of promising computational methods (e.g. Quantitative Structure-Activity Relationships (QSARs), Structure-Activity Relationships (SARs) and/or expert systems) for the evaluation of genotoxicity is needed, especially when very limited information on impurities is available. To gain an overview of how computational methods are used internationally in the regulatory assessment of pharmaceutical impurities, the current regulatory documents were reviewed. The software recommended in the guidelines (e.g. MCASE, MC4PC, Derek for Windows) or used practically by various regulatory agencies (e.g. US Food and Drug Administration, US and Danish Environmental Protection Agencies), as well as other existing programs were analysed. Both statistically based and knowledge-based (expert system) tools were analysed. The overall conclusions on the available in silico tools for genotoxicity and carcinogenicity prediction are quite optimistic, and the regulatory application of QSAR methods is constantly growing. For regulatory purposes, it is recommended that predictions of genotoxicity/carcinogenicity should be based on a battery of models, combining high-sensitivity models (low rate of false negatives) with high-specificity ones (low rate of false positives) and in vitro assays in an integrated manner.     

Perry G. Wang (Ed.): Monolithic chromatography and its modern applications

Organic micropollutants such as pharmaceuticals, perfluorinated compounds (PFCs), and pesticides, are important environmental contaminants. To obtain more information regarding their presence in marine organisms, an increasing demand exists for reliable analytical methods for quantification of these micropollutants in biotic matrices. Therefore, we developed extraction procedures and new analytical methods for the quantification of 14 pesticides, 10 PFCs, and 11 pharmaceuticals in tissue of marine organisms, namely blue mussels (Mytilus edulis). This paper presents these optimized analytical procedures and their application to M. edulis, deployed at five stations in the Belgian coastal zone. The methods consisted of a pressurized liquid extraction and solid-phase extraction (SPE) followed by ultra high-performance liquid chromatography coupled to triple quadrupole mass spectrometry for pharmaceuticals and pesticides, and of a liquid extraction using acetonitrile and SPE, followed by liquid chromatography coupled to time-of-flight mass spectrometry for PFCs. The limits of quantification of the three newly optimized analytical procedures in M. edulis tissue varied between 0.1 and 10 ng g(-1), and satisfactory linearities (≥0.98) and recoveries (90-106%) were obtained. Application of these methods to M. edulis revealed the presence of five pharmaceuticals, two PFCs, and seven pesticides at levels up to 490, 5, and 60 ng g(-1), respectively. The most prevalent micropollutants were salicylic acid, paracetamol, perfluorooctane sulfonate, chloridazon, and dichlorvos.     

Determination of impurities and counterions of pharmaceuticals by capillary electromigration methods

The review presents a survey of recent applications of high‐performance capillary electromigration methods—capillary zone electrophoresis, nonaqueous capillary electrophoresis, capillary isotachophoresis, micellar electrokinetic chromatography, microemulsion electrokinetic chromatography and capillary electrochromatography—for the determination of impurities of pharmaceuticals, including chiral impurities, for the period 2007–2013. In addition, due to the missing evaluation of the determination of counterions of pharmaceuticals by capillary electromigration methods in the last 20 years, the publications dealing with this topic since 1995 are included in this review. General aspects of both these types of applications of capillary electromigration methods in pharmaceutical analysis are discussed, and detailed experimental conditions used for determination of various chemical impurities and counterions of many particular drugs are described.     

An innovative impurity profiling of esmolol hydrochloride injection using UPLC-MS based multiple mass defect filter,chemometrics and in-silico toxicity prediction

Esmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. The potential toxic impurities in pharmaceuticals at micro levels or trace levels are of increasing concern to both pharmaceutical industries and regulatory agencies, due to their potential risk to human health. The impurity investigation of esmolol   remains incomplete. Thereby, efficient impurities monitoring and potential toxicity assessment should be emphasized to assure drug safety. Impurity profiling methods of esmolol were developed using ultraperformance liquid chromatography plus Q-Exactive Orbitrap tandem mass spectrometry (UPLC-QE-MS) based multiple mass defect filter and chemometrics. Impurities were characterized by both UPLC-QE-MS and reference substance comparison. The toxicities of esmolol impurities were predicted by employing quantitative structure–activity relationship. The results showed that a total of 20 impurities were detected and identified using the above integrated strategy, 14 impurities (EP2-3, EP5-6, EP8-9, EP12-13, EP15-20) have firstly found. EP20 was predicted as hepatotoxic and mutagenic using QSAR model, and its hepatotoxicity were verified in vivo. The EP1 contents showed maximum volatility in all batches, and varied by sample. EP1 and its accompanying product of methanol were measured. This UPLC-MS/MS based chemometrics strategy is useful for monitoring the manufacturing process and quality control of esmolol hydrochloride injection.     

Selective and quantitative analysis of 4-hydroxybenzoate preservatives by microemulsion electrokinetic chromatography

A microemulsion electrokinetic chromatography (MEEKC) method has been developed and validated for the determination of 4-hydroxybenzoates and their impurities. These materials are commonly known as parabens and are widely used as preservatives in foods, cosmetics and pharmaceuticals. The method was shown to be selective and quantitative for the methyl, ethyl, propyl and butyl esters of 4-hydroxybenzoic acid. An internal standard, 4-hydroxyacetophenone, was employed to improve injection precision and detector linearity. In addition, 4-hydroxybenzoic acid, the major degradent, could also be monitored at the 0.1% (m/m) level. The method was successfully validated for assay and detection of the impurities in 4-hydroxybenzoic acid methyl ester and 4-hydroxybenzoic acid propyl ester samples and for the determination of 4-hydroxybenzoic acid methyl ester in a liquid pharmaceutical formulation. The determination of paraben content by MEEKC in a liquid sample was consistent with HPLC analysis. This work is the first reported validated MEEKC method and shows that the methodology can be successfully implemented into routine quality control testing.     

Impurity analysis of pharmaceuticals using capillary electromigration methods

This review deals with the determination of impurities in pharmaceuticals by electromigration methods in the capillary format. These separation methods are either based on the different effective mobility of the charged analytes (as in zone electrophoresis and isotachophoresis) or include hybrid methods such as micellar electrokinetic chromatography, microemulsion electrokinetic chromatography and electrochromatography. The pharmaceutically active compounds under consideration belong to chemotherapeutic agents, central nervous system drugs, histamine receptor drugs, cardiovascular drugs, anticancer drugs, anti-inflammatory drugs and some other drugs. The review discusses about 150 publications from the period between 1980 and 2007 with special emphasis on the recent trends and gives details about the experimental conditions applied for analyses and the obtained analytical performance parameters.     

A review of chromatographic characterization techniques for biodiesel and biodiesel blends

This review surveys chromatographic technology that has been applied to the characterization of biodiesel and its blends. Typically, biodiesel consists of fatty acid methyl esters produced by transesterification of plant or animal derived triacylglycerols. Primary attention is given to the determination of trace impurities in biodiesel, such as methanol, glycerol, mono-, di-, and triacylglycerols, and sterol glucosides. The determination of the fatty acid methyl esters, trace impurities in biodiesel, and the determination of the biodiesel content of commercial blends of biodiesel in conventional diesel are also addressed.